Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Ltd ADR
(OP:
ESALY
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Jan 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eisai Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
Via
Benzinga
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
December 19, 2022
From
Eisai
Via
JCN Newswire
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.
Via
InvestorPlace
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
December 18, 2022
Both stocks are heading for double-digit gains this year.
Via
The Motley Fool
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
December 14, 2022
From
Eisai
Via
JCN Newswire
Why 2023 Could Be a Big Year for Biogen
December 07, 2022
Investors will soon learn if the company's Alzheimer's treatment gets the green light.
Via
The Motley Fool
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
December 01, 2022
From
Eisai
Via
JCN Newswire
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
November 29, 2022
From
Eisai
Via
JCN Newswire
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
November 23, 2022
From
Eisai
Via
JCN Newswire
Even After This Year’s Melt-Up, Runway Remains for LLY Stock
December 05, 2022
The market hasn't overreacted with its enthusiasm for LLY stock, as the pharma giant makes progress with a blockbuster drug in the making.
Via
InvestorPlace
Can These 2 Stocks Crush the Market Again in 2023?
December 04, 2022
Both are riding the wave of major clinical wins
Via
The Motley Fool
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).
Via
Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
Via
Benzinga
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 29, 2022
From
Eisai
Via
JCN Newswire
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
November 29, 2022
From
BiogenEisai
Via
JCN Newswire
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
November 28, 2022
Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies.
Via
Investor's Business Daily
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that...
Via
Benzinga
2 Stocks Near 52-Week Highs That Could Climb Higher
November 28, 2022
This pair of stocks are bucking the trend and they could climb even higher.
Via
The Motley Fool
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
November 22, 2022
From
Eisai
Via
JCN Newswire
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
November 15, 2022
Via
Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
Via
Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
November 14, 2022
Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment.
Via
Benzinga
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
October 29, 2022
Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future.
Via
The Motley Fool
Is Biogen a Buy After It Boosted Guidance?
October 26, 2022
There's a much bigger story for this biotech than its improved 2022 outlook.
Via
The Motley Fool
Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug
October 25, 2022
Biogen's partner, Eisai, will present Phase 3 results for lecanemab next month.
Via
Investor's Business Daily
Biogen Q3 Earnings Preview: Key Items For Investors To Watch
October 24, 2022
Biogen Inc (NASDAQ: BIIB) is scheduled to report its third-quarter earnings on Tuesday during the premarket session amid cautious hope for its neurodegenerative disease programs and an ongoing
Via
Benzinga
3 Alzheimer's Therapy Stocks to Invest in
October 21, 2022
Alzheimer's treatments could make a big winner of these stocks.
Via
The Motley Fool
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
Via
Benzinga
Hey Biogen Investors, Don’t Chase BIIB Stock!
October 05, 2022
If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.